EUCTR2008-000753-35-DK进行中（未招募）不适用
A Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study toAssess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients withBronchiectasis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Provision of informed consent prior to any study specific procedures
- •2. Male or female of non-child bearing potential (defined as amenorrhoeic for 12 months and follicle stimulating hormone (FSH) plasma concentration within the post-menopausal range as defined by the laboratory) or surgically sterile (defined as having undergone bilateral oophrectomy and/or hysterectomy; tubal ligation on its own is not adequate), between 18 and 80 years
- •3. Have a clinical diagnosis of idiopathic or post infective bronchiectasis as diagnosed with a historical high resolution computerised tomography (HRCT) or bronchogram
- •4. Be sputum producers with a history of chronic expectoration on most days of most weeks of the year. Patients should have a history of spontaneously producing an average of 3 ml or more sputum on a daily basis and should be able to provide at least 2 of the 3 required baseline sputum samples
- •5. Have normal laboratory values at Visit 1, unless the investigator considers an abnormality to be clinically irrelevant
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
- •2. Previous randomization of treatment in the present study
- •3. 'Participation (defined as administration of at least one dose of investigational product) in another clinical study within 12 weeks of Visit 1.
- •4. Bronchiectasis associated with a generalised immunodeficiency disorder, where manifestations other than bronchiectasis predominate
- •5. Concomitant diagnosis of significant pulmonary disease other than bronchiectasis or COPD, including symptomatic asthma and allergic bronchopulmonary aspergillosis
- •6. An FEV1 of <30% of predicted normal at Visit 1
- •7. Any ECG abnormality at Visit 1 (including a QTc interval of >450 msec for males and >470 msec for females, or any arrhythmia) which in the opinion of the investigator may put the patient at risk or interfere with study assessments.
- •8. An acute exacerbation (defined as an increase in respiratory symptoms requiring hospitalisation and/or a course of oral glucocorticosteroids and/or antibiotics, either prescribed or self administered); or acute respiratory infection (upper or lower) requiring oral steroids or antibiotics in the 6 weeks prior to Visit 2
- •9. Other acute infections requiring treatment in the 4 weeks prior to Visit 2
- •10. Use of prohibited medications as detailed in Section 6.5 of the Protocol
- •11. A past history of or current clinical or laboratory evidence of renal disease, or a calculated creatinine clearance (Cockcroft-Gault formula) of =60 ml/min at Visit 1
- •12. Any other clinical disease or disorder (including insulin dependent diabetes) which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient’s ability to participate in the study
- •13. History of excessive alcohol consumption or chronic alcohol induced disease
- •14. Donation of >1350 mL of blood in the 12 months or 500 mL of blood in the 3 months before the end of the study
- •15. Suspected or known risk of the patient transmitting HIV, Hepatitis B or C
- •16. Scheduled in patient surgery or hospitalisation during the course of the study
研究者
相似试验
进行中（未招募）
不适用
A Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients with Cystic FibrosisMedDRA version: 9.1Level: LLTClassification code 10011762Term: Cystic fibrosisCystic FibrosisEUCTR2008-001530-27-DKAstraZeneca AB70
进行中（未招募）
不适用
A Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients with Cystic FibrosisMedDRA version: 9.1Level: LLTClassification code 10011762Term: Cystic fibrosisCystic FibrosisEUCTR2008-001530-27-SEAstraZeneca AB70
进行中（未招募）
不适用
A Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients with Cystic FibrosisCystic FibrosisEUCTR2008-001530-27-GBAstraZeneca AB70
已完成
2 期
A Phase II, Randomised, Double-Blind, Placebo-Controlled Study Followed by a Continuing Open Label Study, to Verify the Efficacy and Safty of Intrathecal Administration of KP-100IT using NP022 in Subjects with Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosis (ALS)JPRN-UMIN000022050Tohoku University48
进行中（未招募）
不适用
A Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients with Cystic FibrosisMedDRA version: 9.1Level: LLTClassification code 10011762Term: Cystic fibrosisCystic FibrosisEUCTR2008-001530-27-DEAstraZeneca AB65